Phase 3 Clinical Trials With Primary Completion Dates in May 2020
This is a list of Phase 3 trials with primary completion dates in May 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| BTAI | BioXcel Therapeutics, Inc. | 2020-05-01 | Phase 3 | NCT04268303 | Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia |
| BVXV | BiondVax Pharmaceuticals Ltd. | 2020-05-01 | Phase 3 | NCT03450915 | A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine |
| BYSI | BeyondSpring Inc. | 2020-05-01 | Phase 3 | NCT02504489 | Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC |
| ITCI | Intra-Cellular Therapies, Inc. | 2020-05-01 | Phase 3 | NCT02600507 | Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression |
| LXRX | Lexicon Pharmaceuticals, Inc. | 2020-05-01 | Phase 3 | NCT03521934 | Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial) |
| MIRM | Mirum Pharmaceuticals, Inc. | 2020-05-01 | Phase 3 | NCT03905330 | A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) |
| MMSI | Merit Medical Systems, Inc. | 2020-05-01 | Phase 3 | NCT01387932 | HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer |
| OTIC | Otonomy, Inc. | 2020-05-01 | Phase 3 | NCT03664674 | Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease |
| RETA | Reata Pharmaceuticals, Inc. | 2020-05-01 | Phase 3 | NCT02657356 | Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST |
| SAGE | Sage Therapeutics, Inc. | 2020-05-01 | Phase 3 | NCT03771664 | A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Subjects With Comorbid Major Depressive Disorder and Insomnia |
| SLNO | Soleno Therapeutics, Inc. | 2020-05-01 | Phase 3 | NCT03440814 | A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome |
| SPRO | Spero Therapeutics, Inc. | 2020-05-01 | Phase 3 | NCT03788967 | Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) |
| ZEAL | Zealand Pharma A/S | 2020-05-01 | Phase 3 | NCT03777176 | Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism |